XML 35 R23.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Collaboration Agreements - Summary of Revenue Recognized under Agreement (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2016 | Jun. 30, 2016 | Sep. 30, 2015 | Sep. 30, 2016 | Sep. 30, 2015
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |
Total license and milestone revenue | $ 20,867 |  | $ 13,045 | $ 113,802 | $ 131,430
Collaboration services and other revenue from a related party | 9,235 |  | 6,493 | 33,863 | 24,956
Revenue recognized | 30,102 |  | 19,538 | 147,665 | 156,386
Astellas Agreement [Member] |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |
Total license and milestone revenue | 4,370 |  | 5,120 | 20,727 | 14,672
Collaboration services and other revenue from a related party | 436 |  | 868 | 1,114 | 2,221
Astellas Agreement [Member] | Japan [Member] |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |
License revenue | 3,041 |  | 414 | 3,159 | 942
Milestones revenue | 0 | $ 10,000 | 0 | 10,000 | 0
Total license and milestone revenue | 3,041 |  | 414 | 13,159 | 942
Collaboration services and other revenue from a related party | 144 |  | 57 | 151 | 157
Astellas Agreement [Member] | Europe [Member] |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |
License revenue | 1,330 |  | 4,706 | 7,568 | 13,730
Milestones revenue | 0 |  | 0 | 0 | 0
Total license and milestone revenue | 1,330 |  | 4,706 | 7,568 | 13,730
Collaboration services and other revenue from a related party | 292 |  | 812 | 963 | 2,065
AstraZeneca Agreements [Member] | China-single unit of accounting [Member] |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |
Revenue recognized | 0 |  | 0 | 0 | 0
AstraZeneca Agreements [Member] | U.S./RoW [Member] |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |
License revenue | 16,496 |  | 7,925 | 93,075 | 101,758
Milestones revenue | 0 |  | 0 | 0 | 15,000
Total license and milestone revenue | 16,496 |  | 7,925 | 93,075 | 116,758
Collaboration services and other revenue from a related party | $ 8,784 |  | $ 5,614 | $ 32,723 | $ 22,694

X
- Definition Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue. + References No definition available. + Details
Name: | fgen_CollaborationServicesAndOtherRevenue
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and services revenue and the amount of consideration recognized during the period for milestones. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, non-specified, services during the reporting period. + References No definition available. + Details
Name: | fgen_LicenseFeesAndMilestonesRevenue
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseAndServicesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=fgen_ChinaSingleUnitOfAccountingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |